When should systemic biologic therapy for psoriasis be discontinued?
Saved in:
Main Authors: | Diem-Phuong D. Dao (Author), Jessica N. Pixley (Author), Steven R. Feldman (Author) |
---|---|
Format: | Book |
Published: |
Taylor & Francis Group,
2023-01-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
The cost of biologics for psoriasis is increasing
by: Judy Cheng, et al.
Published: (2014) -
Does hospitalization, independent of other treatment, improve severe chronic skin conditions?
by: Diem-Phuong D. Dao, et al.
Published: (2023) -
Emerging Treatment Regimens in Psoriasis: Are There Advantages Over Current Biologic Therapies?
by: Joeseph Nenow, et al.
Published: (2021) -
Predicting discontinuation of biologic therapy caused by adverse events in psoriasis patients-A Danish nationwide cohort study
by: Mia‐Louise Nielsen, et al.
Published: (2023) -
Racial differences in access to psoriasis biologics
by: Shirley P. Parraga, et al.
Published: (2024)